1. Home
  2. HFRO vs RIGL Comparison

HFRO vs RIGL Comparison

Compare HFRO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HFRO
  • RIGL
  • Stock Information
  • Founded
  • HFRO 2000
  • RIGL 1996
  • Country
  • HFRO United States
  • RIGL United States
  • Employees
  • HFRO N/A
  • RIGL N/A
  • Industry
  • HFRO Finance/Investors Services
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HFRO Finance
  • RIGL Health Care
  • Exchange
  • HFRO Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • HFRO 287.7M
  • RIGL 335.5M
  • IPO Year
  • HFRO N/A
  • RIGL 2000
  • Fundamental
  • Price
  • HFRO $6.02
  • RIGL $39.51
  • Analyst Decision
  • HFRO
  • RIGL Buy
  • Analyst Count
  • HFRO 0
  • RIGL 5
  • Target Price
  • HFRO N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • HFRO 179.8K
  • RIGL 647.0K
  • Earning Date
  • HFRO 01-01-0001
  • RIGL 08-05-2025
  • Dividend Yield
  • HFRO 8.87%
  • RIGL N/A
  • EPS Growth
  • HFRO N/A
  • RIGL N/A
  • EPS
  • HFRO N/A
  • RIGL 5.43
  • Revenue
  • HFRO N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • HFRO N/A
  • RIGL $14.41
  • Revenue Next Year
  • HFRO N/A
  • RIGL $15.97
  • P/E Ratio
  • HFRO N/A
  • RIGL $7.27
  • Revenue Growth
  • HFRO N/A
  • RIGL 105.62
  • 52 Week Low
  • HFRO $4.24
  • RIGL $11.88
  • 52 Week High
  • HFRO $6.45
  • RIGL $39.72
  • Technical
  • Relative Strength Index (RSI)
  • HFRO 79.30
  • RIGL 93.36
  • Support Level
  • HFRO $5.19
  • RIGL $20.28
  • Resistance Level
  • HFRO $6.04
  • RIGL $21.41
  • Average True Range (ATR)
  • HFRO 0.11
  • RIGL 2.05
  • MACD
  • HFRO 0.05
  • RIGL 1.59
  • Stochastic Oscillator
  • HFRO 97.06
  • RIGL 99.16

About HFRO Highland Opportunities and Income Fund of Beneficial Interest

Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: